Notice of Intent to Sole Source – Life Technologies Corporation NOI-CC-25-008722
Summary
AI-generated · Aug 28, 2025AIM V MED CTS 1000ml, DYNABEADS CD3/CD28 CTS 10 ML, HEPES, and RPMI 1640 100ML are required for the Center for Cellular Engineering to manufacture patient cell-based therapies. These materials have been validated for manufacturing and approved by the Center’s Quality Assurance Department; although other sources exist, only Life Technologies Corporation has been approved for use in current manufacturing protocols, so substituting suppliers would require requalification of processes, which would be costly and time-consuming for the government.
This procurement will be conducted under FAR Part 13 Simplified Acquisition Procedures (Subpart 13.106-1(b)(1)) because only one source is reasonably available. No solicitation or quotations will be issued. The government may decide not to compete based on responses. Interested parties may identify their interest and capabilities to supply these materials by submitting information prior to the closing date specified in the announcement.
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for AIM V MED CTS 1000ml, DYNABEADS CD3/CD28 CTS 10 ML, HEPES and RPMI 1640 100ML Center for Cellular Engineering (CCE) uses AIM V MED CTS 1000ml, DYNABEADS CD3/CD28 CTS 10 ML, HEPES and RPMI 1640 100ML, material and reagents for patient care responsibilities and these materials are used to manufacture cell-based therapies for patients. All materials have been validated in manufacturing processes to ensure they are of the appropriate quality and that they produce the desired results. In addition, all materials are approved by the Center for Cellular Engineering Quality Assurance Department. Although the material and reagents are available from several sources, only Life Technologies Corporation has been approved by the Center for Cellular Engineering Quality Assurance Department for use in manufacturing protocols. Substitution with another vendor/contractor would require requalification of processes to accommodate the changes, which will be both costly and time consuming for the government. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.
From Special Notice posted on Aug 27, 2025Notice history
1Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA